Boldly investing in
exceptional people
breakthrough medicine
better outcomes for patients
Built by seasoned investors, operators and entrepreneurs we form a generational investing firm that knows what it takes to deliver for patients and investors.
>0
FDA approved medicines
>$0B
Capital raised
>0
IPOs transacted
0
M&A exits >$1B
A team built to deliver
Leadership
Team
Science Partners
Our approach
Access
Our relationships and reputations have been built over decades. Together, we have unparalleled access to biomedical breakthroughs and bold innovators with whom we partner.
Analysis
As open-minded truth seekers, we apply analytical rigor through a collaborative process, building fundamental conviction to support our decision-making.
Action
We are doers who bring entrepreneurial drive and operational experience to the table. With a track record of integrity and follow-through, we seek to be a trusted partner of choice to teams changing the world.
Alignment
Our values, strategy and conduct are in harmony. When we win, we win together for patients, communities, and our investors.
Patient Impact
Patients are our North Star. With a sense of urgency and purpose, we drive to get life changing medicines into their hands.
Value Creation
Our investors are our long-term partners. We build and back outstanding companies to deliver outsized returns.
Our portfolio
The innovators we support
“Soufflé is fortunate to have Juvia as a partner and investor. Stefan has been a great thought partner throughout Soufflé’s growth, with deep insights on our pipeline, people and fundraising strategies. Sujal joined our board two years ago and brings a rare combination of finance and operating experience that has been invaluable. It does not surprise me that Jakob, Stefan and Sujal have teamed up. They all share a deep sense of right versus wrong, a belief in partnership and collaboration, and a great sense of humor.”
Amir Nashat
Chief Executive Officer
Soufflé Therapeutics has a vision that potent, precise, and safe medicines can be designed and developed for all diseases. The company is redefining how medicines are made by combining proprietary cell-selective technologies to develop safer, stronger, and more durable medicines to improve patient lives. Soufflé's initial programs target facioscapulohumeral muscular dystrophy (FSHD), heart failure, and muscle and metabolic disorders.
Decades
of turning ideas
into impact
for patients
Developed by Revolution Medicines
FDA approved in 2026 for metastatic pancreatic adenocarcinoma
Investor Jakob Loven
Developed by CymaBay Therapeutics
FDA approved in 2024 for primary biliary cholangitis
CEO / CFO Sujal Shah
CSO / SVP R&D Chuck McWherter
VP Corporate Comms Arran Attridge
Developed by Peloton Therapeutics
First FDA approval in 2021 for von Hippel-Lindau disease
Second approval in 2023 for advanced renal cell carcinoma
Investor Stefan Vitorovic
Developed by Praxis Precision Medicines
Relutrigine PDUFA Dec 2026 for rare pediatric epilepsies
Ulixacaltamide PDUFA Jan 2027 for essential tremor
Director and Founding Investor Stefan Vitorovic
Developed by Decibel Therapeutics
FDA approved in 2026 for otoferlin-related hearing loss
Founding Team Member and Investor Stefan Vitorovic
Developed by Merck
First approved by the FDA in 2014 for advanced melanoma
Now approved for 19 different cancers
Program Development Team Lead Alise Reicin
Discovered and developed by Relay Therapeutics
FDA approved in 2026 for FGFR2 fusion+ cholangiocarcinoma
Founding CSO and Director Mark Murcko
Founding Team Member and Investor Jakob Loven
Developed by Eisai and Biogen
FDA approved in 2021 and 2023 for early Alzheimer’s disease
Head Neurodegeneration Development Samantha Budd Haeberlein
Developed by Plexxikon / Roche
FDA approved in 2011 for BRAF-mutant metastatic melanoma
Clinical Development Lead Keith Flaherty
.png&w=640&q=75&dpl=dpl_3GqnNDRRLUjfcvasdAGkeXwZyeep){kind=logo}
Developed by Pfizer
FDA approved in 2012 for advanced renal cell carcinoma
Discovery Lead Mike Varney
Developed by Agouron Pharmaceuticals
FDA approved in 1997 for HIV
Development Lead Mike Varney
Developed by EMD Serono and Pfizer
FDA approved in 2017 for metastatic Merkel cell carcinoma
Head of Global Clinical Development Alise Reicin
Developed by Loxo Oncology and Bayer
FDA approved in 2018 for NTRK fusion-positive solid tumors
Co-founder and Director Keith Flaherty
Developed by Vertex and GlaxoSmithKline
FDA approved in 2003 for HIV-1 infection
Co-inventor Mark Murcko
Together, we can turn ambitious ideas into the next generation of medical breakthroughs.
